Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia.
Plasma Catestatin: A Useful Biomarker for Coronary Collateral Development with Chronic Myocardial Ischemia.
复制标题
DOI：
10.1371/journal.pone.0149062
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Wang G
中科院分区：
文献类型：
--
作者：
Xu W;Yu H;Li W;Gao W;Guo L;Wang G
儿茶素是一种内源性多功能神经内分泌肽。儿茶素是近年来发现的一种新的血管生成细胞因子。本研究旨在探讨慢性心肌缺血患者内源性儿茶素与冠脉侧支循环发育的关系。38例冠状动脉慢性完全闭塞(CTO)患者(CTO组)和38例冠状动脉正常患者(正常组)。在CTO患者中，冠状动脉侧支循环的发展按Rtrop计分方法进行分级。Rtrop评分0~1分为络脉发育不良组，2~3分为络脉发育良好组。采用酶联免疫吸附试验试剂盒检测血浆儿茶素和血管内皮生长因子(VEGF)水平。慢性阻塞性肺疾病组血浆儿茶素水平显著高于正常组(1.97±1.01vs1.36±0.97 ng/ml，P=0.009)。络脉发育良好组的血儿茶素和血管内皮生长因子水平显著高于络脉发育不良组(425.23±140.10 vs 238.48±101.00pg/ml，p=0.018；0.001)。慢性阻塞性肺疾病患者血儿茶素水平与Rtrop评分呈正相关(r=0.4，p=0.013)。而血浆儿茶素水平与血管内皮细胞生长因子无相关性(r=-0.06，p=0.744)。在多元线性回归模型中，调整混杂因素后，血浆儿茶素水平是冠状动脉侧支循环形成的独立因素之一。血浆儿茶素水平与冠脉侧支循环的发展有关。它可能是CTO患者冠状动脉侧支循环发育的有用生物标志物和治疗性血管生成的潜在靶点。
Catestatin is an endogenous multifunctional neuroendocrinepeptide. Recently, catestatin was discovered as a novel angiogenic cytokine. The study was to investigate the associations between endogenous catestatin and coronary collateral development among the patients with chronic myocardial ischemia. Thirty-eight patients with coronary artery chronic total occlusions (CTO) (CTO group) and 38 patients with normal coronary arteries (normal group) were enrolled in the series. Among the patients with CTO, coronary collateral development was graded according to the Rentrop score method. Rentrop score 0–1 collateral development was regarded as poor collateral group and 2–3 collateral development was regarded as good collateral group. Plasma catestatin level and vascular endothelial growth factor (VEGF) were measured by ELISA kits. The plasma catestatin levels in CTO group were significantly higher than that in normal group (1.97±1.01 vs 1.36±0.97ng/ml, p = 0.009). In the CTO group, the patients with good collateral development had significantly higher catestatin and VEGF levels than those with poor collateral development (2.36±0.73 vs 1.61±1.12 ng/ml, p = 0.018; 425.23±140.10 vs 238.48±101.00pg/mL, p<0.001). There is a positive correlation between plasma catestatin levels and Rentrop scores (r = 0.40, p = 0.013) among the patients with CTO. However, there is no correlations between plasma catestatin levels and VEGF (r = -0.06, p = 0.744). In the multiple linear regression models, plasma catestatin level was one of the independent factors of coronary collateral development after adjustment for confounders. Plasma catestatin was associated with coronary collateral developments. It may be a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with CTO.